We are speculating that Immunobiotics is planning on entering the Chinese market:
On June 7, 2010, ImmunoBiotics, Inc. entered into an assignment agreement with SYNORx, Inc. whereby SYNORx assigned its Chinese Pending Patent No. 02820470.0 to the Company in exchange for 6,137,500 shares of the Company’s common stock.
Development Stage